South
Texas
Texas allows compounding activity but state pharmacy scrutiny increases quickly once the FDA flags a peptide for safety or efficacy concerns.
Legal context
Physician demand does not override federal compoundability restrictions, and pharmacies often tighten internal policies for peptides on the FDA radar.
What this means
503A pharmacies generally avoid stocking Category 2 peptides for office use.
Patients may still see aggressive marketing online, but that does not create a lawful compounding pathway.
Therapies with stronger federal support remain materially easier to source.